Use of a dual inhibitor IDO1/TDO (RY103) effectively suppressed IDO1 in a pre-clinical murine pancreatic cancer model [193] and might be a new avenue to be considered in circumventing the inhibitory action of IDO1 in NK cell-mediated cytotoxicity. This evidence concerns the gene IDO1 and familial pancreatic carcinoma.